These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8210642)

  • 21. Interleukin-2-activated human effector lymphocytes mediate cytotoxicity by inducing apoptosis in human leukaemia and solid tumour target cells.
    Knight CR; Rees RC; Platts A; Johnson T; Griffin M
    Immunology; 1993 Aug; 79(4):535-41. PubMed ID: 8104887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy with interleukin-2 after autologous bone marrow transplantation for hematologic malignancies.
    Benyunes MC; Thompson JA; York A; Buckner CD; Fefer A
    Prog Clin Biol Res; 1994; 389():229-38. PubMed ID: 7700905
    [No Abstract]   [Full Text] [Related]  

  • 23. In vitro resistance of the brown Norway rat acute myelocytic leukemia (BNML) to lymphokine-activated killer activity.
    Gaiser JF; Kloosterman TC; Martens AC; Hagenbeek A
    Leukemia; 1993 May; 7(5):736-41. PubMed ID: 8483327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of lymphokine-activated killer cell against human leukemia cells in vitro.
    Teichmann JV; Ludwig WD; Seibt-Jung H; Thiel E
    Blut; 1989 Jul; 59(1):21-4. PubMed ID: 2502211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective purging by human interleukin-2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells.
    Gambacorti-Passerini C; Rivoltini L; Fizzotti M; Rodolfo M; Sensi ML; Castelli C; Orazi A; Polli N; Bregni M; Siena S
    Br J Haematol; 1991 Jun; 78(2):197-205. PubMed ID: 2064957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lymphokine-activated killer cytotoxicity against leukaemic blast cells.
    Tratkiewicz JA; Szer J; Boyd RL
    Clin Exp Immunol; 1990 Apr; 80(1):94-9. PubMed ID: 2323104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospects for interleukin-2 therapy in hematologic malignant neoplasms.
    Malkovska V; Sondel PM
    J Natl Cancer Inst Monogr; 1990; (10):69-72. PubMed ID: 2189478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relationship between multi-drug resistance and resistance to natural-killer-cell and lymphokine-activated killer-cell lysis in human leukemic cell lines.
    Treichel RS; Olken S
    Int J Cancer; 1992 Jan; 50(2):305-10. PubMed ID: 1370437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cancer therapy by using bispecific antibody].
    Azuma A; Niitani H; Okumura K
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1535-42. PubMed ID: 1872618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-2-based immunotherapy in the management of minimal residual disease in acute leukemia patients.
    Foa R; Meloni G; Guarini A; Vignetti M; Marchis D; Tosti S; Gillio Tos A; Mandelli F; Gavosto F
    Recent Results Cancer Res; 1993; 131():207-14. PubMed ID: 8210640
    [No Abstract]   [Full Text] [Related]  

  • 31. Interleukin-2 in autologous bone marrow transplantation.
    Charak BS
    Natl Med J India; 1993; 6(1):19-22. PubMed ID: 8453356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Taurine attenuates recombinant interleukin-2-activated, lymphocyte-mediated endothelial cell injury.
    Finnegan NM; Redmond HP; Bouchier-Hayes DJ
    Cancer; 1998 Jan; 82(1):186-99. PubMed ID: 9428497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lymphokine-activated killing of autologous and allogeneic short-term cultured head and neck squamous carcinomas.
    Leess FR; Bredenkamp JK; Lichtenstein A; Mickel RA
    Laryngoscope; 1989 Dec; 99(12):1255-61. PubMed ID: 2601539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
    Kimoto Y
    Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-2 induction of lymphokine-activated killer activity in the peripheral blood of an acute lymphoblastic leukaemia patient--case study.
    Dickinson AM; Lennard AL; Cartner R; Proctor SJ
    Leukemia; 1992 Sep; 6(9):957-60. PubMed ID: 1518307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extracorporeal immunomodulation in patients with hepatocellular carcinoma with lymphokine activated killer cells.
    Saibara T; Fujikawa M; Iwamura S; Matsuura Y; Ido E; Sakaeda H; Tomita A; Matsunaga Y; Maeda T; Onishi S
    Prog Clin Biol Res; 1990; 337():459-67. PubMed ID: 2162063
    [No Abstract]   [Full Text] [Related]  

  • 37. Selective antitumor activity of lymphokine-activated killer cells in vitro.
    Zhukova OS; Lebedinskaya OV; Shubina IZh; Gerasimova GK; Karamzin AM; Kiselevskii MV
    Bull Exp Biol Med; 2007 Jan; 143(1):132-5. PubMed ID: 18019030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytotoxicity of cytokine-induced killer cells coated with bispecific antibody against acute myeloid leukemia cells.
    Kaneko T; Fusauch Y; Kakui Y; Okumura K; Mizoguchi H; Oshimi K
    Leuk Lymphoma; 1994 Jul; 14(3-4):219-29. PubMed ID: 7950910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transforming growth factor-beta inhibits lymphokine activated killer cytotoxicity of bone marrow cells: implications for the graft-versus-leukemia effect in irradiation allogeneic bone marrow chimeras.
    Billiau AD; Sefrioui H; Overbergh L; Rutgeerts O; Goebels J; Mathieu C; Waer M
    Transplantation; 2001 Jan; 71(2):292-9. PubMed ID: 11213076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The preclinical assessment of the activity and pharmacological action of native human interleukin-2].
    Malakhova NV; Treshchalin ID; Iobadze MS; Abronina IF; Bykovskaia SN; Iushkov SF; Pereverzeva ER; Syrkin AB; Raushenbakh MO
    Patol Fiziol Eksp Ter; 1990; (2):32-4. PubMed ID: 2381746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.